Articles from Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026.
By Emmaus Life Sciences, Inc. · Via Business Wire · November 18, 2026
Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company focused on sickle cell disease (SCD), today announced the advancement of two real-world evidence (RWE) initiatives across the Gulf Cooperation Council (GCC) region and the signing of an exclusive distribution agreement in Libya, marking the company's entry into North Africa.
By Emmaus Life Sciences, Inc. · Via Business Wire · November 12, 2026
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).
By Emmaus Life Sciences, Inc. · Via Business Wire · August 31, 2026
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026.
By Emmaus Life Sciences, Inc. · Via Business Wire · August 14, 2026
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026.
By Emmaus Life Sciences, Inc. · Via Business Wire · May 15, 2026
Emmaus Life Sciences Reports Annual Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025.
By Emmaus Life Sciences, Inc. · Via Business Wire · March 30, 2026
Emmaus Life Sciences Announces Strategic Transaction
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a royalty on NIT’s product sales.
By Emmaus Life Sciences, Inc. · Via Business Wire · December 30, 2025